Musculoskeletal senescence: a moving target ready to be eliminated

被引：63

作者：

Baar, Marjolein P. ^{[1
,2
]}

Perdiguero, Eusebio ^{[3
]}

Munoz-Canoves, Pura ^{[3
,4
,5
]}

de Keizer, Peter L. J. ^{[1
]}

机构：

[1] Univ Utrecht, Univ Med Ctr Utrecht, Div Biomed Genet, Ctr Mol Med,Dept Mol Canc Res, Univ Weg 100, NL-3584 CG Utrecht, Netherlands

[2] Erasmus Univ, Med Ctr, Dept Mol Genet, Rotterdam, Netherlands

[3] Pompeu Fabra Univ UPF, Dept Expt & Hlth Sci, CIBERNED, Barcelona, Spain

[4] ICREA, Madrid, Spain

[5] Spanish Natl Ctr Cardiovasc Res CNIC, Madrid, Spain

来源：

CURRENT OPINION IN PHARMACOLOGY | 2018年 / 40卷

关键词：

MESENCHYMAL STEM-CELLS; SKELETAL-MUSCLE REGENERATION; MARROW STROMAL CELLS; CELLULAR SENESCENCE; SATELLITE CELLS; KNEE OSTEOARTHRITIS; ARTICULAR-CARTILAGE; PROGENITOR CELLS; DNA-DAMAGE; POSTTRAUMATIC OSTEOARTHRITIS;

D O I：

10.1016/j.coph.2018.05.007

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Aging is the prime risk factor for the broad-based development of diseases. Frailty is a phenotypical hallmark of aging and is often used to assess whether the predicted benefits of a therapy outweigh the risks for older patients. Senescent cells form as a consequence of unresolved molecular damage and persistently secrete molecules that can impair tissue function. Recent evidence shows senescent cells can chronically interfere with stem cell function and drive aging of the musculoskeletal system. In addition, targeted apoptosis of senescent cells can restore tissue homeostasis in aged animals. Thus, targeting cellular senescence provides new therapeutic opportunities for the intervention of frailty-associated pathologies and could have pleiotropic health benefits.

引用

页码：147 / 155

页数：9

共 85 条

[31]

Role of Interleukin-1 Inhibitors in Osteoarthritis An Evidence-Based Review [J].